|
**Overview**: Apolipoproteins A1 B Panel**Introduction**: The Apolipoproteins A1 B Panel is a diagnostic tool designed to assess cardiovascular risk using serum samples. In India, dyslipidemia contributes to high CVD burden (leading cause of death, ~27 percent mortality), with apoB/apoA1 ratio a superior predictor of risk compared to LDL-C alone (elevated apoB in 30-50 percent of metabolic syndrome cases). High prevalence of metabolic syndrome (20-30 percent urban adults), diabetes, and premature atherosclerosis in South Asians. High morbidity from underdiagnosis in asymptomatic individuals, limited lipid subfraction testing in rural areas, and delayed statin/lifestyle intervention. Per biochemistry practices aligned with ICMR and Indian Heart Association guidelines, the test employs spectrophotometry for apoA1, apoB, and ratio calculation over 1-2 days with high sensitivity/specificity, valuable for refined CV risk stratification. This diagnostic falls under lipid profile screening and targets adults with suspected dyslipidemia or high CV risk, addressing accurate detection to guide preventive therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise risk assessment, facilitating management, and reducing CVD events. Its serum-based approach ensures reliable detection.**Other Names**: Apo A1 B Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: ApoB/apoA1 ratio validated for risk; in India, promoted in CVD prevention programs.**Purpose**: The test assesses 3 parameters including apoA1 and apoB to calculate ratio, evaluate CV risk, inform statin/lifestyle interventions.**Test Parameters**: 1. Apolipoprotein A1, 2. Apolipoprotein B, 3. Apo B/A1 Ratio.**Pretest Condition**: Fasting 10-12 hours required; patients should report family CVD history, obesity, diabetes, or hypertension.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on family CVD, diabetes, hypertension, smoking, diet, exercise.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated dyslipidemia including heart attack/stroke, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or non-fasting can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated apoB/apoA1 ratio indicates high CV risk, necessitating lifestyle/statin intervention. Normal may require follow-up in high-risk individuals.**Specialist Consultation**: Cardiologists or physicians should be consulted for risk management.**Additional Supporting Tests**: Full lipid profile, hs-CRP for confirmation.**Test Limitations**: Ratio may not capture all risks; comprehensive approach required.**References**: Indian Journal of Cardiology 2024, Dyslipidemia Studies India 2023. |
